Item 7.01 Regulation FD Disclosure
On May 10, 2022, Moleculin Biotech, Inc. (the “Company”), issued a press release
to announce that it has received approval from the MHRA to proceed with its
amended first-in-human Phase 1a study to evaluate safety and pharmacokinetics of
WP1122 in healthy volunteers for the treatment of COVID-19 (MB-301). The
protocol amendment allows for a higher ratio of diluting excipients to drug
substance to facilitate a faster and simpler mixing procedure prior to drug
administration.
A copy of the press release is attached to this report as Exhibit 99.1 and is
incorporated by reference herein.
The information contained in Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, is being furnished and shall not be “filed” for the
purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor
shall it be incorporated by reference in any filing under the Exchange Act or
the Securities Act of 1933, as amended (“Securities Act”), unless specifically
identified therein as being incorporated by reference.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated May 10, 2022 104 Cover page Interactive Data File (formatted as Inline XBRL document)
© Edgar Online, source Glimpses
postbrexitcompliance.com 